- Acute anterior wall myocardial infarction:
- Initially PO 7.5mg BD*2/7, then 15mg BD *2/7, then 30mg BD
- Target dose: 30mg BD
- Begin 24 hours after onset of symptoms and continue dose for 6/52
- Hypertension:
- Initially PO 15mg OD
- May increase dose at 4-week intervals
- Usual effective dose: PO 30mg OD
- Maximum daily dose: 60 mg/day, administer OD or divided BD
- Tablet:
- 30mg
- Can be taken with or without food
- Diuretics should be discontinued 2-3 days prior to initiating zofenopril, if possible.
- Restart diuretic after blood pressure is stable, if needed.
- If diuretic can be discontinued prior to therapy, begin with 15mg/day with close supervision until stable blood pressure.
- Start dose at 7.5mg/day if these measures cannot be taken.
ACE Inhibitor.
It acts primarily on the suppression of the plasma renin-angiotensin aldosterone system thus decreasing plasma angiotensin II concentration, leading to decreased vasopressor activity and reduced aldosterone secretion
- 1st-dose hypotension
- Symptomatic hypotension
- Increased blood urea and creatinine concentration
- Hyperkalaemia
- Cholestatic jaundice
- Cough
- Neutropenia
- Agranulocytosis
- Thrombocytopenia
- Anaemia
- Proteinuria
- Marked elevation of liver enzymes
- Hypersensitivity to class/ingredients
- History of angioneurotic oedema associated with previous ACE inhibitor therapy.
- Hereditary/idiopathic angioneurotic oedema.
- Severe hepatic impairment
- Women of child-bearing potential unless protected by effective contraception.
- Bilateral renal artery stenosis or unilateral renal artery stenosis in cases of a solitary single kidney
- Pregnancy
- Diabetes
- Sacubitril/valsartan
- Racecadotril
- Sirolimus
- Everolimus
- Temsirolimus
- Potassium-sparing diuretics
- Aliskiren
Drug Status
Availability | Prescription only |
Pregnancy | Contraindicated |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Bifril | 30mg | Tablet | 28’s | Menarini International | Phillips Therapeutics |